The neuroprotective effects of micronized PEA (PEA-m) formulation on diabetic peripheral neuropathy in mice
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- Mice with diabetes induced by streptozotocin, plus controls; numbers not stated in the abstract
- Dose used in the study
- Micronised palmitoylethanolamide 10 mg/kg daily by oral gavage, starting 2 weeks after streptozotocin
- Duration
- To 16 weeks
- What was measured
- Mechanical and thermal hyperalgesia, motor function, mast cell activation, nerve growth factor, nerve histology, oxidative and nitrosative stress, cytokines, angiogenesis, apoptosis, spinal microglia, p38 MAPK and NF-kappa-B, and PPAR-alpha involvement.
What the authors reported
This laboratory study found:
- Micronised PEA reduced mechanical and thermal hyperalgesia and motor changes, and lowered mast cell activation and nerve growth factor.
- It reduced nerve damage, oxidative and nitrosative stress, cytokines, angiogenesis and apoptosis, and inhibited spinal microglial activation, phospho-p38 and NF-kappa-B.
- The authors link the effects at least in part to PPAR-alpha.
Limits of this study
A mouse model of diabetic neuropathy; it cannot show effect in people. Animal numbers are not in the abstract. Funding and conflicts not stated in the abstract.
Source
PubMed 31344333 · doi:10.1096/fj.201900538R
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.